BerGenBio ASA announced appointment of Cristina Oliva, MD as chief medical officer (CMO), effective April 25, 2022. Cristina joins the senior leadership team heading up clinical development of BerGenBio's selective AXL inhibitor programs. Cristina is board-certified oncologist and brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and clinical research organizations (CROs). Most recently Cristina was vice president, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd, prior to Cristina role at IQVIA, Cristina held senior positions leading oncology development programs for Nordic Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.